Latest results from the PUP-GCP clinical trial: a low inhibitor rate in previously untreated patients with severe hemophilia A treated with octanate

被引：0
|
作者：
Klukowska, A. [1 ]
Jansen, M. [2 ]
Komrska, V. [3 ]
Laguna, P. [1 ]
Vdovin, V. [4 ]
Knaub, S. [5 ]
机构：
[1] Med Univ Warsaw, Dept Paediat Haematol & Oncol, Warsaw, Poland
[2] Octapharma Prod Gesell mbH, Vienna, Austria
[3] Univ Hosp Motol, Dept Pediat Haematol & Oncol, Prague, Czech Republic
[4] Izmaylovo Childrens Hosp, Haematol Ctr, Moscow, Russia
[5] OCTAPHARMA AG, Clin R&D Dept, Lachen, Switzerland
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 20
页数：2
相关论文
共 50 条
  • [21] Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq®, a New Generation Recombinant FVIII of Human Origin
    Liesner, Raina
    Abashidze, Marina
    Aleinikova, Olga
    Altisent, Carmen
    Belletrutti, Mark J.
    Borel-Derlon, Annie
    Carcao, Manuel
    Chambost, Herve
    Chan, Anthony
    Dubey, Leonid
    Ducore, Jonathan M.
    Abubacker, Fouzia Nambiathayil
    Gattens, Michael
    Gruel, Yves
    Kavardakova, Natalya
    Khorassani, Mohamed
    Klukowska, Anna
    Konigs, Christoph
    Lambert, Thierry
    Lohade, Sunil
    Sigaud, Marianne
    Turea, Valentin
    Wu, John K.
    Vdovin, Vladimir
    BLOOD, 2016, 128 (22)
  • [22] Risk of bleeding and inhibitor development after circumcision of Previously Untreated (PUPs) or Minimally Treated (MTPs) severe hemophilia A patients
    Elalfy, M.
    Elbarbary, N.
    Eldebeiky, M.
    El Danasoury, A.
    HAEMOPHILIA, 2012, 18 : 89 - 89
  • [23] Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial
    Sidonio, Robert F., Jr.
    Knoll, Christine
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Antmen, Ali Bulent
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Maggiore, Caterina
    Engl, Werner
    Allen, Geoffrey
    Tangada, Srilatha
    BLOOD, 2021, 138
  • [24] Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada
    Fischer, Kathelijn
    Lassila, Riitta
    Peyvandi, Flora
    Gatt, Alexander
    Hollingsworth, Rob
    Lambert, Thierry
    Kaczmarek, Radek
    Bettle, Amanda
    Samji, Nasrin
    Rivard, Georges-etienne
    Carcao, Manuel
    Iorio, Alfonso
    Makris, Mike
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [25] Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
    Wilson, Amanda
    Kragh, Nana
    Mshijid, Jerome
    Dumont, Jennifer
    Willemze, Annemieke
    Santagostino, Elena
    Zhang, Chuanwu
    Kulkarni, Roshni
    von Drygalski, Annette
    Chowdary, Pratima
    BLOOD, 2022, 140 : 5610 - 5611
  • [26] EFFICACY AND SAFETY OF RURIOCTOCOG ALFA PEGOL IN PERIOPERATIVE MANAGEMENT: INTERIM RESULTS FROM AN OPEN-LABEL MULTICENTER CLINICAL TRIAL IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A
    Peyvandi, F.
    Sidonio, R. F., Jr.
    Stasyshyn, O.
    Alamelu, J.
    Glosli, H.
    Le, P. -Q.
    Albayrak, C.
    Antmen, A. B.
    Lopez, M. Fernandez
    Maggiore, C.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2022, 28 : 48 - 48
  • [27] Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a
    Sidonio, Robert F., Jr.
    Thompson, Alexis A.
    Peyvandi, Flora
    Albayrak, Canan
    Yeoh, Seoh Leng
    Lam, Joyce
    Maggiore, Caterina
    Engl, Werner
    Allen, Geoffrey
    Tanada, Srillatha
    BLOOD, 2021, 138
  • [28] Risk of inhibitor development in previously treated patients with positive inhibitor history or low titer of inhibitor at baseline: results of a survey of hemophilia experts
    Marcucci, M.
    Fisher, K.
    Kenet, G.
    Young, G.
    Walker, I
    Thabane, L.
    Iorio, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 34 - 34
  • [29] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
    Iorio, A.
    Halimeh, S.
    Holzhauer, S.
    Goldenberg, N.
    Marchesini, E.
    Marcucci, M.
    Young, G.
    Bidlingmaier, C.
    Brandao, L. R.
    Ettingshausen, C. E.
    Gringeri, A.
    Kenet, G.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1256 - 1265
  • [30] FINAL RESULTS FROM THE NUPROTECT STUDY OF NUWIQ® (SIM OCT OCOG ALFA) TREATMENT IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A
    Liesner, R. J.
    Jansen, M.
    Knaub, S.
    HAEMATOLOGICA, 2019, 104 : 10 - 10
12345